title: Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention.
abstract: The hemostatic system in its multiple components displays an intricate organization in time which is characterized by circadian (approximately 24-hour), circaseptan (approximately 7-day), menstrual (approximately monthly), and circannual (approximately yearly) bioperiodicities. The interaction of the rhythms of the variables participating in hemostasis determine transient risk states of thromboembolic events, including myocardial infarction and stroke, and of hemorrhage and hemorrhagic events, each with a unique timing. The circadian staging of the rhythms in vascular, cellular, and coagulation factors that favors blood coagulation and thrombosis coincides with the daily minimum in fibrinolytic activity; as a result there is elevated risk in the morning of acute myocardial infarction and stroke. Similar hemostatic rhythms may determine the epidemiology of thromboembolic and hemorrhagic events during the week, month and year. This article focuses on the large-amplitude circadian rhythms operative in the hemostatic system. Their implication for preventive and curative pharmacotherapy of hemostatic disorders is presented, with discussion of related problems.
authors.affiliation: University of Minnesota, HealthPartners Medical Group, Regions Hospital, St. Paul 55101, USA. Erhard.X.Haus@Healthpartners.com
authors.forename: Erhard
authors.initials: E
authors.lastname: Haus
mesh_terms: D001341:Autonomic Nervous System / Q000502:physiology; D001777:Blood Coagulation; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D002909:Chronobiology Phenomena / Q000502:physiology*; D002940:Circadian Rhythm / Q000502:physiology; D005260:Female; D005342:Fibrinolysis; D006487:Hemostasis / Q000502:physiology*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008597:Menstrual Cycle; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors